Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial2026 · 2 citations
2. 2Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience2024 · 2 citations
3. 3Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma2024
4. 4Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial2025
5. 5Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study2025